1. INTRODUCTION {#sec1}
===============

Metabotropic glutamate receptors (mGlus) are obligate homodimers, yet the possibility that various mGlus might also form heterodimeric signalling complexes, possessing pharmacology beyond that of the homodimeric receptor isoforms, has garnered significant interest \[[@r1]-[@r7]\]. Of these, the existence of mGlu~2/4~ heterodimers has now been validated by multiple labs both *in vitro* and in native tissues \[[@r7]-[@r12]\]. Data from Vanderbilt are consistent with the presence of an mGlu4 homodimer at striatopallidal synapses and an mGlu2/4 heterodimer at cortico-striatal synapses. Moreover, mGlu~4~ Positive Allosteric Modulator (PAM) ligands that also activate the mGlu~2/4~ heterodimers demonstrate efficacy in animal models of anxiety and psychosis (akin to mGlu~2~ PAMs), whereas ligands that only activate homodimeric mGlu~4~ do not show efficacy in these models, but display robust anti-Parkinsonian activity (Fig. **[1](#F1){ref-type="fig"}**) \[[@r8], [@r9], [@r13], [@r14]\]. Recent modeling and docking studies suggest that there are two overlapping PAM binding pockets on mGlu~4~ - a shallow pocket and a deep pocket \[[@r15]\]. Interestingly, mGlu~4~ PAM ligands that also activate the mGlu~2/4~ heterodimer, such as **4** and **5**, \[[@r15]-[@r18]\] were modeled to bind in the smaller, shallow pocket (possibly *via* an induced fit) \[[@r15]\] mechanism) whereas mGlu~4~ PAMs that exclusively activate the homodimer, such as **1**-**3**, \[[@r8], [@r9], [@r19], [@r20]\] bind in the larger pocket.

To date, no PAM tools exist that only activate the mGlu~2/4~ heterodimer. In order to more fully understand the observed *in vivo* activity of PAMs that also activate the mGlu~2/4~ heterodimer, highly selective mGlu~2/4~ heterodimer PAMs, without activity at either the mGlu~2~ or mGlu~4~ homodimers, are required. In this article, initial attempts towards identifying a selective mGlu~2/4~ heterodimer PAM are described, as well as the unique medicinal chemistry and molecular pharmacology challenges associated with such an endeavor.

2. MATERIALS AND METHODS {#sec2}
========================

2.1. Chemical Methods {#sec2.1}
---------------------

### 2.1.1. General {#sec2.1.1}

All NMR spectra were recorded on a 400 MHz AMX Bruker NMR spectrometer. ^1^H and ^13^C chemical shifts are reported in δ values in ppm downfield with the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, b = broad, m = multiplet), integration, coupling constant (Hz). Low-resolution mass spectra were obtained on an Agilent 6120 or 6150 with ESI source. Method A: MS parameters were as follows: Fragmentor: 70, capillary voltage: 3000 V, nebulizer pressure: 30 psig, drying gas flow: 13 L/min, drying gas temperature: 350ºC. Samples were introduced *via* an Agilent 1290 UHPLC comprised of a G4220A binary pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV absorption was generally observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: Waters Acquity BEH C18, 1.0 x 50 mm, 1.7 um. Gradient conditions: 5% to 95% CH~3~CN in H~2~O (0.1% TFA) over 1.4 min, hold at 95% CH~3~CN for 0.1 min, 0.5 mL/min, 55ºC. Method B: MS parameters were as follows: fragmentor: 100, capillary voltage: 3000 V, nebulizer pressure: 40 psig, drying gas flow: 11 L/min, drying gas temperature: 350ºC. Samples were introduced *via* an Agilent 1200 HPLC comprised of a degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, G1315D DAD, and a Varian 380 ELSD (if applicable). UV absorption was generally observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: Thermo Accucore C18, 2.1 x 30 mm, 2.6 um. Gradient conditions: 7% to 95% CH~3~CN in H~2~O (0.1% TFA) over 1.6 min, hold at 95% CH~3~CN for 0.35 min, 1.5 mL/min, 45ºC. High-resolution mass spectra were obtained on an Agilent 6540 UHD Q-TOF with ESI source. MS parameters were as follows: fragmentor: 150, capillary voltage: 3500 V, nebulizer pressure: 60 psig, drying gas flow: 13 L/min, drying gas temperature: 275 ºC. Samples were introduced *via* an Agilent 1200 UHPLC comprised of a G4220A binary pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV absorption was observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: Agilent Zorbax Extend C18, 1.8 µm, 2.1 x 50 mm. Gradient conditions: 5% to 95% CH~3~CN in H~2~O (0.1% formic acid) over 1 min, hold at 95% CH~3~CN for 0.1 min, 0.5 mL/min, 40ºC. For compounds that were purified on a Gilson preparative reversed-phase HPLC, the system comprised of a 333 aqueous pump with solvent-selection valve, 334 organic pump, GX-271 or GX-281 liquid handler, two column switching valves, and a 155 UV detector. UV wavelength for fraction collection was user-defined, with absorbance at 254 nm always monitored. Method: Phenomenex Axia-packed Luna C18, 30 x 50 mm, 5 µm column. Mobile phase: CH~3~CN in H~2~O (0.1% TFA). Gradient conditions: 0.75 min equilibration, followed by user-defined gradient (starting organic percentage, ending organic percentage, duration), hold at 95% CH~3~CN in H~2~O (0.1% TFA) for 1 min, 50 mL/min, 23ºC. Solvents for extraction, washing and chromatography were HPLC grade. All reagents were purchased from Aldrich Chemical Co. and were used without purification.

#### 2.1.1.1. General Procedure for Compounds 7/8 {#sec2.1.1.1}

To a solution of **6** (0.13 mmol, 1 eq) in THF (0.5 mL, 0.26M) in a 1-dram vial at room temperature aniline/ heterocyclic amine (0.13 mmol, 1 eq) was added in one portion. The vial was sealed and the mixture heated to reflux for 16 hours to yield crude **7**. For compounds **8**, after cooling to room temperature, N,N-Diisopropylethylamine (0.143 mmol, 1.1 eq) and isobutyl chloroformate (0.143 mmol, 1.1 eq) were added and the reaction was stirred for 30 minutes at room temperature. For primary carboxamide congeners, ammonium hydroxide (1mL) was added and the reaction was stirred for an additional hour at room temperature. For substituted amide analogs, desired amine (0.26, 2 eq) was added instead of ammonium hydroxide and stirring was continued for an additional 2 hours. The reaction was then diluted with ether (1mL), the layers were separated and the aqueous layer was extracted with ether (3x2mL). The organic layers were passed through a phase separator and concentrated *in vacuo*, and then crude product was purified using preparative HPLC (30x50mm column, MeCN/0.1% TFA: Water, 4 min gradient) to yield desired compounds **8**.

##### 2.1.1.1.1. (1S,2R)-N^1^-(4-chloro-4-fluorophenyl)cyclohexa-ne-1,2-dicarboxamide (8b) {#sec2.1.1.1.1}

White solid, 24% yield. ^1^HNMR (400 MHz, DMSO) δ 10.0 (s, 1H), 7.82 (dd, *J* = 12.5, 2.0, 1H), 7.49 (t, *J* = 9.1, 1H), 7.35 (dd, *J* = 9.1, 2.0, 1H), 7.09 (bs, 1H), 6.75 (bs, 1H), 2.85 (m, 1H), 2.51 (m, 1H), 2.21-2.10 (m, 1H), 2.09-2.00 (m, 1H), 1.77-1.64 (m, 3H), 1.61-1.50 (m, 1H), 1.46-1.29 (m, 2H); ^13^C NMR (150 MHz, MeOD); ^13^CNMR (100 MHz, DMSO) δ 175.5, 173.5, 156.9 (d, *J~CF~* = 243.5), 140.3 (d, *J~CF~* = 10.2), 130.2, 115.9 (*J~CF~* = 3.1), 112.0 (d, *J~CF~* = 17.8), 107.0 (d, *J~CF~* = 26.2), 43.3, 42.6, 27.4, 25.8, 24.0, 22.2. LCMS: 0.867 min; M+H= 299.2; \>99% at 215 and 254 nm.

#### 2.1.1.2. General Procedure for Compounds 11 {#sec2.1.1.2}

To a solution of **9** (0.06 mmol, 1 eq) in DMF (0.5 mL) in a 1-dram vial, HATU (0.126 mmol, 2 eq) and N,N-Diisopropylethylamine (0.190 mmol, 3 eq) were added. The reaction was stirred for 10 minutes, then amine (0.076 mmol, 1.2 eq) was added and the reaction was stirred for 8 hours at room temperature. The crude reaction mixture was diluted with water (1.5mL) and extracted with DCM (3x2mL) and the organics were passed through a phase separator and concentrated *in vacuo*. Crude product was purified using preparative HPLC (30x50mm column, MeCN/0.1% TFA:Water, 4 min gradient) to yield desired compounds **11**.

##### 2.1.1.2.1. 2-(3-cyano-4-iosbutoxyphenyl)-4-methyl-N-(tetr-ahydro-2H-pyran-4-yl)thiazole-5-carboxamide (11a) {#sec2.1.1.2.1}

Yellow solid, 63% yield. ^1^HNMR (400MHz, CDCl~3~) δ 8.11 (d, *J* = 2.2, 1H), 8.04 (dd, *J* = 8.6, 2.2, 1H), 6.99 (d, *J* = 8.6, 1H), 5.72 (d, *J* = 7.5, 1H), 4.16 (m, 1H), 4.00 (m, 2H), 3.89 (d, *J* = 6.6, 2H), 3.52 (td, *J* = 11.6, 1.5, 2H), 2.71 (s, 3H), 2.19 (sep, *J* = 6.6, 1H), 1.97-2.05 (m, 2H), 1.58 (qd, *J* = 11.6, 4.1, 2H), 1.08 (d, *J* = 6.6, 6H); ^13^C NMR (100 MHz, CDCl~3~) δ 164.6, 162.5, 161.1, 132.6, 132.1, 126.1, 125.9, 115.6, 112.8, 103.1, 75.9, 66.9, 46.7, 33.3, 28.3, 19.2, 17.6. LCMS: 1.043 min; M+H= 400.2; \>99% at 215 and 254 nm.

2.2. Biological Methods {#sec2.2}
-----------------------

### 2.2.1. mGlu Receptor Thallium Flux Assays {#sec2.2.1}

Cell lines: Polyclonal rat mGlu~2~/HEK/GIRK, rat mGlu~4~/HEK/GIRK and rat mGlu~4~/mGlu~2~ HEK/GIRK cells were used for these studies. For dye loading, media was exchanged with Assay Buffer (HBSS containing 20 mM HEPES, pH 7.4) using an ELX405 microplate washer (BioTek), leaving 20 μL/well, followed by addition of 20 μL/ well 2× FluoZin-2 AM (164 nM final) indicator dye (Life Technologies, prepared as a DMSO stock and mixed in a 1:1 ratio with pluronic acid F-127) in Assay Buffer. After 1h incubation at room temperature, dye was exchanged with Assay Buffer, leaving 20 μL/well, and allowed to sit for 15 minutes. Thallium flux was measured at room temperature using a Functional Drug Screening System 7000 (FDSS 7000, Hamamatsu). Baseline readings were taken (2 images at 1 Hz; excitation, 470 ± 20 nm; emission, 540 ± 30 nm), and test compounds (2×) were added in a 20μL volume and incubated for 140 s before the addition of 10 μL of Thallium Buffer with or without agonist (5×). Data were collected for an additional 2.5 min and analyzed using using Dotmatics software (Bishops Stortford, Hertz, UK) using a four parameter logistical curve fit. For direct GIRK assays, methods were performed as described in 22.

3. RESULTS AND DISCUSSION {#sec3}
=========================

3.1. Chemistry and Pharmacology {#sec3.1}
-------------------------------

Several years ago, the discovery of VU0155041 (**4**) as a novel mGlu~4~ PAM with efficacy in Parkinson's disease (PD) models was reported \[[@r16], [@r17]\]. SAR for this series at the mGlu~4~ homodimer proved 'steep' and recalcitrant. Subsequent efforts by Lundbeck produced a carboxamide congener, Lu AF21934 (**5**), which displayed efficacy in models of PD and also anxiety and psychosis \[[@r13], [@r14]\]. We found this report intriguing, as we could not replicate the *in vivo* pharmacology observed with **5** in anxiety and psychosis models across a structurally diverse array of mGlu~4~ PAMs. Further investigation showed that **5** was a PAM of both mGlu~~~4~~~ homodimers and the mGlu~2/4~ heterodimer, whereas PAMs devoid of activity at the mGlu~2/4~ heterodimer did not show efficacy in animal models of anxiety and psychosis, but retained activity in PD models \[[@r8], [@r9]\]. Thus, attention focused on an attempt to optimize **4** and **5** for activity at the mGlu~2/4~ heterodimer, with a hope that the 'steep' and/or 'flat' SAR at the homodimer would not be repeated. However, based on the small, shallow binding pocket predicted from the modeling studies \[[@r15]\], challenges were anticipated. [Fig. (**[2](#F2){ref-type="fig"}**)](#F2){ref-type="fig"} highlights the envisioned optimization plan for the general core of **4**/**5**.

In short order, over 100 analogs of **4**/**5** were readily prepared following the route outlined in Scheme **[1](#s1){ref-type="scheme"}**. Starting from commercial, *cis*-anhydrides **6**, treatment with anilines or heterocyclic amines in refluxing THF afforded carboxy amides **7** in yields ranging from 32-89%. These carboxylic acid analogs **7** were evaluated as mGlu~2/4~ PAMs, and then the acids were further elaborated into both primary carboxamide and substituted amide congeners **8**.

The 'steep' and/or 'flat' SAR that plagued the mGlu~4~ homodimer optimization effort within this series was present for the mGlu~2/4~ heterodimer as well \[[@r16], [@r17]\]. All 100 analogs synthesized and screened against the mGlu~2/4~ heterodimer produced EC~50~s \> 10 μM, whereas the in-plate control **5** uniformly displayed good PAM activity (rat EC~50~ = 1.9 μM, 89% Glu Max). [Fig. (**[3](#F3){ref-type="fig"}**)](#F3){ref-type="fig"} highlights exemplary weak mGlu~2/4~ PAMs from this effort that potentiated the EC~20~ greater than two-fold. Introduction of unsaturation into the cyclohexyl ring, bicyclic congeners and or ring-contracted analogs (cyclobutyl or cyclopentyl) reported them all to be inactive. Carboxylic acid bioisosteres, secondary amides, tertiary amides and *trans*-congeners were all devoid of mGlu~2/4~ PAM activity.

Having exhausted these mGlu~2/4~ PAM ligands in an unsuccessful optimization campaign, we turned towards a screening effort to identify new chemical matter. Here, the team chose to pilot a screen utilizing an internal FDA approved drug collection of 1,152 unique and structurally diverse compounds. For this, we employed our mGlu~2/4~ heterodimer HEK293 cell line with native coupling to G protein-coupled inwardly rectifying potassium channels, or GIRK (using thallium flux as a read-out). This screening exercise identified febuxostat (**9**), an FDA-approved xanthine oxidase inhibitor (Fig. **[4](#F4){ref-type="fig"}**) \[[@r21]\], as a weak mGlu~2/4~ PAM hit (EC~50~ = 3.4 μM, pEC~50~ = 5.47±0.07, 52.4±3.7% Glu Max). Aesthetically, **9** was appealing, as it possessed elements structurally related to **4**, and a selectivity check against homodimeric mGlu~4~ (in a G~qi5~ calcium assay, which was running to support an internal mGlu~4~ PAM program) showed no activity (EC~50~ \> 30 μM). However, **9** was not CNS penetrant (rat brain: plasma partitioning coefficient, K~p~ = 0.03), and the optimization effort would need to address this liability early, while hopefully retaining the favorable profile of an FDA-approved drug.

^a^Reagents and conditions. **a**) HNR1R2, HATU, DIEA, CH2Cl2, rt, 8 h, 65-90%.

Based on the improved activity and CNS penetration of **5** over **4**, we first converted **9** into the analogous carboxamide **10** (Fig. **[5](#F5){ref-type="fig"}**). Once again, SAR appeared conserved across the two chemotypes, with **10** displaying improved mGlu~2/4~ PAM activity (EC~50~ = 2.2 µM, pEC~50~ = 5.65±0.07, 61.0±6.6% Glu Max) and significantly enhanced CNS penetration (rat K~p~ = 3.44, an \~100-fold increase). In our mGlu~4~ calcium assay (CHO cells, promiscuous G~qi5~ reporter), **10** was similarly devoid of PAM activity; however, when assessed for selectivity *versus* both mGlu~4~ and mGlu~2~ homodimers in HEK293 cells with the GIRK readout, selectivity was lost (rat mGlu~4~ GIRK EC~50~ = 2.1 µM, pEC~50~ = 5.68±0.05, 51.3±4.0% Glu Max and rat mGlu~2~ GIRK EC~50~ = 1.2 µM, pEC~50~ = 5.92±0.01, 117.1±9.1% Glu Max). We next evaluated activity in non-transfected HEK293 cells (*e.g*., HEK293 cells without mGlu~4~, mGlu~2~ or mGlu~2/4~ expressed), and noted activity in the absence of the mGlu receptors. These data suggested that **10** might be directly activating GIRK channels \[[@r22]\]. This proved to be the case, with **10** showing An EC~50~ of 1 uM against GIRK1-containing channels (GIRK1/2, GIRK1/4), but no activation of homomeric GIRK2 channels, confirming that the data collected in the mGlu~2/4~ HEK293 cells with GIRK readout reflected direct activation of GIRK1-containing channels.

Despite this setback, we elected to synthesize a 22-member library of secondary and tertiary amide analogs of **9**, derivatives **11** (Scheme **[2](#s2){ref-type="scheme"}**), to assess if the GIRK activity was a result of this chemotype in general (*e.g*., a GIRK pharmacophore) or unique pharmacology of the primary carboxamide congener **10**. Analogs **11** were readily prepared from **9** in a single HATU-mediated amide coupling step in good yields (65-90%). Prior to evaluating the secondary and tertiary amide analogs **11**, we first evaluated GIRK activity, and interestingly, these derivatives had no direct activation of GIRK channels. Thus, we assessed analogs **11** as mGlu~2/4~ PAMs (Table **[1](#T1){ref-type="table"}**); however, SAR was steep, and only three of the twenty-two analogs demonstrated weak PAM activity. Here, we were looking for a weak hit for which to dive deeper into a multi-dimensional optimization campaign, but first we needed to assess selectivity *versus* mGlu~4~ and mGlu~2~. Gratifyingly, all three analogs were inactive at the homodimeric mGlu~4~ (rat EC~50~s \>30 μM, HEK293 GIRK line), which was encouraging as previous mGlu~2/4~ PAMs, such as **4** and **5**, also potentiated mGlu~4~.

However, counter screening against rat mGlu~2~ indicated that analogs **11** were comparably potent, but more efficacious mGlu~2~ PAMs (Table **[2](#T2){ref-type="table"}**), and thus more accurately characterized as mGlu~2~ PAMs; importantly, analogs **11** represent a novel, CNS penetrant mGlu~2~ PAM chemotype \[[@r5]\]. Like **10**, analogs **11** showed good CNS penetration (rat K~p~s \>2), but modification of the carboxylic acid moiety in **9** ablated the favorable disposition properties of the FDA-approved febuxostat \[[@r21]\], yielding high predicted hepatic clearance across species (human CL~hep~ \>14 mL/min/kg and rat CL~hep~ \>62 mL/min/kg). Thus, the first foray into discovering mGlu~2/4~ heterodimer PAMs met with disappointment, but key lessons were learned moving forward.

CONCLUSION
==========

In summary, we have detailed our initial attempts at the discovery and optimization of mGlu~2/4~ heterodimer PAMs, much needed tools to clearly define the pharmacology of this unique heterodimeric receptor complex. SAR of the mGlu~4~ PAMs **4** and **5**, which also potentiate the mGlu~2/4~ heterodimer, was steep, with little structural modifications tolerated. A screen of a collection of 1,152 FDA approved drugs yielded febuxostat (**9**), an FDA-approved xanthine oxidase inhibitor, as a modest mGlu~2/4~ PAM. Optimization to remove zwitterionic character provided analogs with improved PAM activity and CNS penetration (\>100-fold); however, these primary carboxamide analogs proved to be GIRK1/2 and GIRK 1/4 activators -- not mGlu~2/4~ PAMs. Other analogs proved to be comparably potent, but more efficacious, mGlu~2~ PAMs, yet representing novel, CNS penetrant chemotypes. While this report describes a failed optimization campaign, it did provide key lessons moving forward, relevant to other researchers attempting to develop heterodimer ligands, as well as new leads for the development of GIRK1/2 and GIRK1/4 activators and mGlu~2~ PAMs. Based on these lessons, we have initiated a new, large high-throughput screening campaign to identify selective mGlu~2/4~ PAM hits, employing five counter-screening assays, and results will be reported in due course.
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![Structures representative of mGlu~4~ homodimer PAMs **1**-**3**, and PAMs **4** and **5** that activate both the mGlu~4~ homodimer and the mGlu~2/4~ heterodimer.](LDDD-16-1387_F1){#F1}

![Multi-dimensional optimization plan for **4** and **5** to assess activity at the mGlu~2/4~ heterodimer.](LDDD-16-1387_F2){#F2}

![Exemplar weak rat mGlu~2/4~ PAMs resulting from the optimization of **4** and **5** in rat HEK293 cells measuring thallium flux (*n* =3).](LDDD-16-1387_F3){#F3}

![Synthesis of mGlu~2/4~ PAM analogs **8**^a^.\
*^a^*Reagents and conditions: (a) ArNH~2~ or ArNHR (or HetNH~2~ or HetNHR), THF, reflux, 16 hr, 32-89%; (b) (i) isobutyl chloroformate, DIEA, THF, rt, 30 min, (ii) NH~4~OH, 1 hr (20-40%) or HNR~1~R~2~, 2 hr (35-60%).](LDDD-16-1387_S1){#s1}

![Structure of febuxostat (**9**) and initial optimization plan. Replace the carboxylic acid and potential zwitterionic character, due to the basic thiazole, to improve CNS penetration and mGlu~2/4~ PAM potency.](LDDD-16-1387_F4){#F4}

![Conversion of febuxostat (**9**) to the analogous carboxamide (**10**) improves rat mGlu~2/4~ PAM potency and CNS penetration, consistent with SAR in the **4**/**5** series.](LDDD-16-1387_F5){#F5}

![Synthesis of amide analogs **11**^a^.](LDDD-16-1387_S2){#s2}

###### Structures and rat activities for mGlu~2/4~ PAM analogs 11.

  -------------------------------------------------------------------------------
  **Cpd**   **NR~1~R~2~**               **mGlu~2/4~**\           **mGlu~2/4~**\
                                        **EC~50~ (μM)^a^**\      **pEC~50~**\
                                        **\[% Glu Max ±SEM\]**   **(±SEM)**
  --------- --------------------------- ------------------------ ----------------
  **11a**   ![](LDDD-16-1387_t1b.jpg)   5.2\                     5.28±0.03
                                        \[35±[@r2]\]             

  **11b**   ![](LDDD-16-1387_t1c.jpg)   2.3\                     5.63±0.13
                                        \[24±[@r1]\]             

  **11c**   ![](LDDD-16-1387_t1d.jpg)   0.76\                    6.12±0.23
                                        \[28±[@r3]\]             
  -------------------------------------------------------------------------------

^a^Thallium mobilization assays with rat mGlu~2/4~-HEK293 cells performed in the presence of an EC~20~ fixed concentration of glutamate; values represent means from three (*n*=3) independent experiments performed in triplicate.

###### Structures and rat activities for mGlu~2~ PAM analogs 11.

  -------------------------------------------------------------------------------
  ![](LDDD-16-1387_t2-1.jpg)                                          
  ---------------------------- ---------------------------- --------- -----------
  **11a**                      ![](LDDD-16-1387_t2-a.jpg)   4.8\      5.32±0.02
                                                            (73±30)   

  **11b**                      ![](LDDD-16-1387_t2-b.jpg)   2.4\      5.62±0.11
                                                            (53±6)    

  **11c**                      ![](LDDD-16-1387_t2-c.jpg)   0.77\     6.11±0.08
                                                            (57±6)    
  -------------------------------------------------------------------------------

^a^Thallium mobilization assays with rat mGlu~2~-HEK293 cells performed in the presence of an EC~20~ fixed concentration of glutamate; values represent means from three (*n*=3) independent experiments performed in triplicate.
